Cargando…

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study

Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattarai, Shristi, Klimov, Sergey, Mittal, Karuna, Krishnamurti, Uma, Li, Xiaoxian (Bill), Oprea-Ilies, Gabriela, Wetherilt, Ceyda Sonmez, Riaz, Ansa, Aleskandarany, Mohammed A., Green, Andrew R., Ellis, Ian O., Cantuaria, Guilherme, Gupta, Meenakshi, Manne, Upender, Agboola, Johnson, Baskovich, Brett, Janssen, Emiel A. M., Callagy, Grace, Walsh, Elaine M., Mehta, Anurag, Dogra, Atika, Shet, Tanuja, Gajaria, Pooja, Traina, Tiffany, Nggada, Haruna A., Omonisi, Abidemi, Ahmed, Saad A., Rakha, Emad A., Rida, Padmashree, Aneja, Ritu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678933/
https://www.ncbi.nlm.nih.gov/pubmed/31319547
http://dx.doi.org/10.3390/cancers11070995
_version_ 1783441219802628096
author Bhattarai, Shristi
Klimov, Sergey
Mittal, Karuna
Krishnamurti, Uma
Li, Xiaoxian (Bill)
Oprea-Ilies, Gabriela
Wetherilt, Ceyda Sonmez
Riaz, Ansa
Aleskandarany, Mohammed A.
Green, Andrew R.
Ellis, Ian O.
Cantuaria, Guilherme
Gupta, Meenakshi
Manne, Upender
Agboola, Johnson
Baskovich, Brett
Janssen, Emiel A. M.
Callagy, Grace
Walsh, Elaine M.
Mehta, Anurag
Dogra, Atika
Shet, Tanuja
Gajaria, Pooja
Traina, Tiffany
Nggada, Haruna A.
Omonisi, Abidemi
Ahmed, Saad A.
Rakha, Emad A.
Rida, Padmashree
Aneja, Ritu
author_facet Bhattarai, Shristi
Klimov, Sergey
Mittal, Karuna
Krishnamurti, Uma
Li, Xiaoxian (Bill)
Oprea-Ilies, Gabriela
Wetherilt, Ceyda Sonmez
Riaz, Ansa
Aleskandarany, Mohammed A.
Green, Andrew R.
Ellis, Ian O.
Cantuaria, Guilherme
Gupta, Meenakshi
Manne, Upender
Agboola, Johnson
Baskovich, Brett
Janssen, Emiel A. M.
Callagy, Grace
Walsh, Elaine M.
Mehta, Anurag
Dogra, Atika
Shet, Tanuja
Gajaria, Pooja
Traina, Tiffany
Nggada, Haruna A.
Omonisi, Abidemi
Ahmed, Saad A.
Rakha, Emad A.
Rida, Padmashree
Aneja, Ritu
author_sort Bhattarai, Shristi
collection PubMed
description Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients’ prognosis. Methods: We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222), Nigeria (n = 180), and India (n = 242); total n = 1407}. All TNBC samples were stained with the same anti-AR antibody using the same immunohistochemistry protocol, and samples with ≥1% of AR-positive nuclei were deemed AR-positive TNBCs. Results: AR status shows population-specific patterns of association with patients’ overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. Conclusion: AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted.
format Online
Article
Text
id pubmed-6678933
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66789332019-08-19 Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study Bhattarai, Shristi Klimov, Sergey Mittal, Karuna Krishnamurti, Uma Li, Xiaoxian (Bill) Oprea-Ilies, Gabriela Wetherilt, Ceyda Sonmez Riaz, Ansa Aleskandarany, Mohammed A. Green, Andrew R. Ellis, Ian O. Cantuaria, Guilherme Gupta, Meenakshi Manne, Upender Agboola, Johnson Baskovich, Brett Janssen, Emiel A. M. Callagy, Grace Walsh, Elaine M. Mehta, Anurag Dogra, Atika Shet, Tanuja Gajaria, Pooja Traina, Tiffany Nggada, Haruna A. Omonisi, Abidemi Ahmed, Saad A. Rakha, Emad A. Rida, Padmashree Aneja, Ritu Cancers (Basel) Brief Report Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients’ prognosis. Methods: We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222), Nigeria (n = 180), and India (n = 242); total n = 1407}. All TNBC samples were stained with the same anti-AR antibody using the same immunohistochemistry protocol, and samples with ≥1% of AR-positive nuclei were deemed AR-positive TNBCs. Results: AR status shows population-specific patterns of association with patients’ overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. Conclusion: AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted. MDPI 2019-07-17 /pmc/articles/PMC6678933/ /pubmed/31319547 http://dx.doi.org/10.3390/cancers11070995 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Bhattarai, Shristi
Klimov, Sergey
Mittal, Karuna
Krishnamurti, Uma
Li, Xiaoxian (Bill)
Oprea-Ilies, Gabriela
Wetherilt, Ceyda Sonmez
Riaz, Ansa
Aleskandarany, Mohammed A.
Green, Andrew R.
Ellis, Ian O.
Cantuaria, Guilherme
Gupta, Meenakshi
Manne, Upender
Agboola, Johnson
Baskovich, Brett
Janssen, Emiel A. M.
Callagy, Grace
Walsh, Elaine M.
Mehta, Anurag
Dogra, Atika
Shet, Tanuja
Gajaria, Pooja
Traina, Tiffany
Nggada, Haruna A.
Omonisi, Abidemi
Ahmed, Saad A.
Rakha, Emad A.
Rida, Padmashree
Aneja, Ritu
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
title Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
title_full Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
title_fullStr Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
title_full_unstemmed Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
title_short Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
title_sort prognostic role of androgen receptor in triple negative breast cancer: a multi-institutional study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678933/
https://www.ncbi.nlm.nih.gov/pubmed/31319547
http://dx.doi.org/10.3390/cancers11070995
work_keys_str_mv AT bhattaraishristi prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT klimovsergey prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT mittalkaruna prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT krishnamurtiuma prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT lixiaoxianbill prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT opreailiesgabriela prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT wetheriltceydasonmez prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT riazansa prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT aleskandaranymohammeda prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT greenandrewr prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT ellisiano prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT cantuariaguilherme prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT guptameenakshi prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT manneupender prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT agboolajohnson prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT baskovichbrett prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT janssenemielam prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT callagygrace prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT walshelainem prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT mehtaanurag prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT dograatika prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT shettanuja prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT gajariapooja prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT trainatiffany prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT nggadaharunaa prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT omonisiabidemi prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT ahmedsaada prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT rakhaemada prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT ridapadmashree prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy
AT anejaritu prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy